Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemivameran
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Cemivameran (Pfizer mRNA COVID-19 vaccine, 2024-2025 Formula) is an mRNA-based vaccine co-developed by Pfizer and BioNTech to prevent COVID-19 caused by the SARS-CoV-2 virus. It consists of a nucleoside-modified messenger RNA (modRNA) formulated in lipid nanoparticles (LNPs). The mRNA encodes the prefusion-stabilized spike (S) protein of the SARS-CoV-2 Omicron KP.2 variant. Upon intramuscular administration, host cells translate the mRNA to transiently express the KP.2 spike antigen, which stimulates neutralizing antibody production and cellular immune responses. The vaccine is marketed under the brand name Comirnaty KP.2 for individuals aged 12 years and older, and is available under Emergency Use Authorization (EUA) as the Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) for younger pediatric populations.
- Brand names
- ComirnatyComirnaty KP.2
- Other names
- Pfizer mRNA COVID-19 vaccinePfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on cemivameran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemivameran.